Pulmonary alveolar microlithiasis

Area of Science:

• Pulmonary Medicine
• Rare Diseases
• Genetics

Background:

• Pulmonary alveolar microlithiasis (PAM) is a rare lung disease characterized by hydroxyapatite microlith accumulation in alveoli.
• It often presents incidentally and progresses slowly to respiratory insufficiency over decades.
• Recent genetic findings link PAM to a deficiency in the sodium-phosphate cotransporter NPT2B.

Purpose of the Study:

• To review the epidemiology, molecular pathophysiology, and diagnostic approaches to PAM.
• To discuss clinical manifestations, radiographic and pathologic features, and current management strategies.
• To explore emerging insights for potential therapeutic trials based on disease pathogenesis.

Main Methods:

• Literature review of epidemiology, genetics, and pathophysiology.
• Analysis of diagnostic, clinical, radiographic, and pathologic features.
• Synthesis of current management and future therapeutic strategies.

Main Results:

• PAM is linked to NPT2B deficiency, enabling new animal models.
• Disease course is typically slow, leading to progressive respiratory insufficiency.
• No definitive treatments exist, but pathogenesis insights guide future research.

Conclusions:

• Genetic discoveries have advanced understanding of PAM pathogenesis.
• Animal models provide valuable tools for studying the disease.
• Further research into disease mechanisms is crucial for developing effective treatments.